Magnus Medical sits at the high end of psychiatric neuromodulation, commercializing accelerated, image-guided TMS based on the SAINT protocol for severe depression. Its PMA-level approval and strong Stanford-derived clinical narrative position it as one of the most clinically credible next-generation TMS companies.